FDA Approves Nasacort AQ For Children

The U.S. Food and Drug Administration (FDA) has approved Sanofi-aventis’ Nasacort AQ® Nasal Spray (triamcinolone acetonide) for children two to five years of age for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis (Medical News Today).

Latest posts by admin aapc (see all)

Read the complete Article

Login as a member or sign up for free to get uninterrupted access to AAPC blog posts and stay updated on industry news through our monthly newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *